Validated Products & Commercial Pipelines

Opis™ Embolization Deivce

Effective vascular occlusion is the primary goal in treating aneurysms, AVMs/AVFs, acute hemorrhage, and varicose veins, etc. Whether the objective is preventing rupture, arresting bleeding, or eliminating blood reflux, the success of the procedure depends on the device used. However, current market standards—such as metallic coils, vascular plugs, liquid agents, microspheres—often fall short. These existing technologies are plagued by limitations that complicate procedures and compromise clinical outcomes.

Next-generation embolization device for endovascular occlusion (artery/vein, peripheral/neurovascular)

Significant advantage over coils, plugs, fluid embolics, and microspheres

  • Highly expansible (up to 32x)
  • Intrinsic thrombogenic (collagen induced)
  • Minimal tension (soft expansion)
  • Fully bioabsorbable (2-3 months)
  • Easy to use

Engineered for delivery through catheter, and only expands outside of catheter

Indicated to occlude arteries, veins or aneurysms

Indicated to be performed under fluoroscopy or ultrasound guidance

  • Expansible collagen sponge enhances compact occlusion filling the whole cavity
  • Collagen initiates hemostasis rapidly
  • Histology analysis shows rapid thrombus formation immediately after implantation (as the left figure shows)

Swift™ Vascular Closure Device

Swift

  • Pivotal clinical trial completed in 2024 with 236 enrolled patients, demonstrating a 98.25% success rate and a 0% complication rate.
  • Collagen sponge is implanted just above the vascular puncture site, and can be fully reabsorbed in 2-3 months.
  • Approved by NMPA* in 2025.

*The National Medical Products Administration (NMPA), formerly known as the CFDA, is China’s regulator for drugs, devices and cosmetics.

Swift Pro

  • Intuitive operation with a foolproof design.
  • Implanted just above the vascular puncture site, the collagen sponge can be fully reabsorbed in 2-3 months.
  • Expected to receive European CE mark in 2026.

Swift Ultima

  • Next generation Collabond™ technology endows collagen sponge with adhesive capacity and further thrombogenic ability.
  • Time to Hemostasis (TTH) and Time to Ambulation (TTA) can be significantly reduced
  • Potentially capable of larger bore indication
  • Pivotal clinical trial anticipated in 2026

Safer™ Esophagus Deviation Balloon Catheter

A novel esophageal retraction balloon catheter, designed for esophageal protection during radiofrequency ablation for atrial fibrillation.

Now in commercial use, Safer supports both transoral and transnasal insertion pathways and has already been adopted in a growing number of clinical centers.

Demonstrated excellent performance in hundreds of conscious‑sedation procedures, reinforcing its effectiveness and ease of use.

Peek™ Intravascular Ultrasonic Navigation System

Novel ultrasound system for super-selecting challenging vasculature under direct intravascular ultrasound guidance.

Indications such as in situ fenestration for aortic endografts and adrenal venous sampling (AVS) are under development.